Latest news
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo has entered into a feasibility…
Iconovo Accelerator Program
On June 1st, 2023 Iconovo launched its Iconovo Accelerator to facilitate the opportunities for the company’s customers to obtain EU funding for the development…
Press releases
Apr 14, 2026, 15:40
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Staff change
Apr 14, 2026, 15:40
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Staff change
Mar 17, 2026, 16:05
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 17, 2026, 16:05
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 10, 2026, 08:05
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 10, 2026, 08:05
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 02, 2026, 16:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Mar 02, 2026, 16:20
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 27, 2026, 18:20
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 27, 2026, 18:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 24, 2026, 20:50
News
IR
Swedish
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Feb 24, 2026, 20:50
News
IR
English
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Feb 13, 2026, 08:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 13, 2026, 08:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 12, 2026, 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Prospectus
Feb 12, 2026, 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Prospectus
Feb 12, 2026, 08:30
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Feb 12, 2026, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Jan 15, 2026, 10:15
News
IR
English
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Jan 15, 2026, 10:15
News
IR
Swedish
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se